AlphaGrep UK’s BridgeBio Pharma BBIO Stock Holding History

AlphaGrep UK’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,010	Closed	-$224K	–	748
2026 Q1	$224K	Sell	3,010 -710	-19%	-$51.5K	0.06%	671
2025 Q4	$285K	Buy	+3,720	New	+$244K	0.1%	461

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

AlphaGrep UK's BBIO Position: Q2 2026 in Review

AlphaGrep UK sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 3,010 shares — an estimated $224K sold.

AlphaGrep UK first reported a position in BBIO in Q4 2025 and held it in 2 quarters. The position peaked at $285K in Q4 2025. 439 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

AlphaGrep UK reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
AlphaGrep UK sold 3,010 BridgeBio Pharma shares in Q2 2026, an estimated $224K.
AlphaGrep UK first reported a position in BridgeBio Pharma in Q4 2025 and held it in 2 quarters.
AlphaGrep UK's BridgeBio Pharma position peaked at $285K in Q4 2025.
439 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on AlphaGrep UK's 13F filing for Q2 2026, filed 14 Aug 2026.